Literature DB >> 31422690

TRPV1 (Transient Receptor Potential Vanilloid 1) Cardiac Spinal Afferents Contribute to Hypertension in Spontaneous Hypertensive Rat.

Julia Shanks1, Sharon D B de Morais1, Lie Gao1, Irving H Zucker1, Han-Jun Wang1,2.   

Abstract

Hypertension is associated with increased sympathetic activity. A component of this sympathoexcitation may be driven by increased signaling from sensory endings from the heart to the autonomic control areas in the brain. This pathway mediates the so-called cardiac sympathetic afferent reflex, which is also activated by coronary ischemia or other nociceptive stimuli in the heart. The cardiac sympathetic afferent reflex has been shown to be enhanced in the heart failure state and in renal hypertension. However, little is known about its role in the development or progression of hypertension or the phenotype of the sensory endings involved. To investigate this, we used the selective afferent neurotoxin, resiniferatoxin (RTX) to chronically abolish the cardiac sympathetic afferent reflex in 2 models of hypertension; the spontaneous hypertensive rats (SHRs) and AngII (angiotensin II) infusion (240 ng/kg per min). Blood pressure (BP) was measured in conscious animals for 2 to 8 weeks post-RTX. Epidural application of RTX to the T1-T4 spinal segments prevented the further BP increase in 8-week-old SHR and lowered BP in 16-week-old SHR. RTX did not affect BP in Wistar-Kyoto normotensive rats nor in AngII-infused rats. Epicardial application of RTX (50 µg/mL) in 4-week-old SHR prevented the BP increase whereas this treatment does not lower BP in 16-week-old SHR. When RTX was administered into the L2-L5 spinal segments of 16-week-old SHR, no change in BP was observed. These findings indicate that signaling via thoracic afferent nerve fibers may contribute to the hypertension phenotype in the SHR but not in the Ang II infusion model of hypertension.

Entities:  

Keywords:  angiotensin; blood pressure; sensory neurons; sympathetic nerve activity

Mesh:

Substances:

Year:  2019        PMID: 31422690      PMCID: PMC6739148          DOI: 10.1161/HYPERTENSIONAHA.119.13285

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  73 in total

1.  Emerging excitatory role of cardiovascular sympathetic afferents in pathophysiological conditions.

Authors:  Alberto Malliani; Nicola Montano
Journal:  Hypertension       Date:  2002-01       Impact factor: 10.190

Review 2.  Evidence for a critical role of the sympathetic nervous system in hypertension.

Authors:  Guido Grassi; Venkata S Ram
Journal:  J Am Soc Hypertens       Date:  2016-03-04

Review 3.  Cardiac resynchronization therapy in heart failure patients with less severe left ventricular dysfunction.

Authors:  Ofek Y Hai; Robert J Mentz; Faiez Zannad; Maurizio Gasparini; Gaetano M De Ferrari; Jean-Claude Daubert; Johannes Holzmeister; Carolyn S P Lam; Thierry Pochet; Alphons Vincent; Cecilia Linde
Journal:  Eur J Heart Fail       Date:  2014-12-03       Impact factor: 15.534

Review 4.  The carotid body as a therapeutic target for the treatment of sympathetically mediated diseases.

Authors:  Julian F R Paton; Paul A Sobotka; Marat Fudim; Zoar J Engelman; Zoar J Engleman; Emma C J Hart; Fiona D McBryde; Ana P Abdala; Nepthali Marina; Alexander V Gourine; Mel Lobo; Nik Patel; Amy Burchell; Laura Ratcliffe; Angus Nightingale
Journal:  Hypertension       Date:  2012-11-19       Impact factor: 10.190

Review 5.  Peripheral cardiac sympathetic hyperactivity in cardiovascular disease: role of neuropeptides.

Authors:  Julia Shanks; Neil Herring
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2013-09-04       Impact factor: 3.619

6.  Clonidine reverses the slowly developing hypertension produced by low doses of angiotensin II.

Authors:  V J Gorbea-Oppliger; G D Fink
Journal:  Hypertension       Date:  1994-06       Impact factor: 10.190

Review 7.  Antihypertensive drugs and the sympathetic nervous system.

Authors:  Sara Del Colle; Fulvio Morello; Franco Rabbia; Alberto Milan; Diego Naso; Elisabetta Puglisi; Paolo Mulatero; Franco Veglio
Journal:  J Cardiovasc Pharmacol       Date:  2007-11       Impact factor: 3.105

8.  Enhanced cardiac sympathetic afferent reflex involved in sympathetic overactivity in renovascular hypertensive rats.

Authors:  Guo-Qing Zhu; Yao Xu; Li-Min Zhou; Yue-Hua Li; Le-Ming Fan; Wei Wang; Xing-Ya Gao; Qi Chen
Journal:  Exp Physiol       Date:  2009-04-03       Impact factor: 2.969

Review 9.  Integrative Physiological Aspects of Brain RAS in Hypertension.

Authors:  Sharon D B de Morais; Julia Shanks; Irving H Zucker
Journal:  Curr Hypertens Rep       Date:  2018-02-26       Impact factor: 5.369

10.  Circulating angiotensin II deteriorates left ventricular function with sympathoexcitation via brain angiotensin II receptor.

Authors:  Keisuke Shinohara; Takuya Kishi; Yoshitaka Hirooka; Kenji Sunagawa
Journal:  Physiol Rep       Date:  2015-08
View more
  3 in total

1.  Activation of bradykinin-sensitive pericardial afferents increases systemic venous tone in conscious rats.

Authors:  Douglas S Martin; Erin Vogel; Jessica Freeling; Casey Reihe
Journal:  Auton Neurosci       Date:  2019-12-26       Impact factor: 3.145

2.  Central Blockade of E-Prostanoid 3 Receptor Ameliorated Hypertension Partially by Attenuating Oxidative Stress and Inflammation in the Hypothalamic Paraventricular Nucleus of Spontaneously Hypertensive Rats.

Authors:  Fang-Fang Wang; Xiao-Jing Yu; Qiu-Yue Yi; Juan Ba; Xiao-Lian Shi; Jin-Jun Liu; Kai-Li Liu; Li-Yan Fu; Qing Su; Hong-Bao Li; Kai B Kang; Shu-Qiu Wang; Hong-Li Gao; Jie Qi; Ying Li; Guo-Qing Zhu; Yu-Ming Kang
Journal:  Cardiovasc Toxicol       Date:  2020-11-09       Impact factor: 3.231

3.  The Impact of Insulin Resistance on Cardiovascular Control During Exercise in Diabetes.

Authors:  Masaki Mizuno; Norio Hotta; Rie Ishizawa; Han-Kyul Kim; Gary Iwamoto; Wanpen Vongpatanasin; Jere H Mitchell; Scott A Smith
Journal:  Exerc Sport Sci Rev       Date:  2021-07-01       Impact factor: 6.642

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.